BOSS ZHIPIN-W
02076
TME-SW
01698
BIDU-SW
09888
4
NTES-S
09999
5
JD HEALTH
06618
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -0.69%74.99B | 1.50%59.06B | 2.68%41.04B | 6.09%22.95B | 6.68%75.52B | 6.16%58.18B | 7.39%39.97B | 5.31%21.63B | 2.57%70.79B | 2.37%54.81B |
Operating income | -0.69%74.99B | 1.50%59.06B | 2.68%41.04B | 6.09%22.95B | 6.68%75.52B | 6.16%58.18B | 7.39%39.97B | 5.31%21.63B | 2.57%70.79B | 2.37%54.81B |
Operating expenses | -1.87%-62.47B | -4.49%-48.6B | -5.05%-33.24B | -7.68%-17.87B | -6.64%-61.33B | -5.79%-46.51B | -7.22%-31.65B | -5.68%-16.59B | -3.10%-57.51B | -2.96%-43.97B |
Gross profit | -11.75%12.52B | -10.40%10.46B | -6.32%7.8B | 0.87%5.08B | 6.85%14.19B | 7.68%11.67B | 8.04%8.32B | 4.09%5.04B | 0.33%13.28B | 0.03%10.84B |
Selling expenses | 7.95%-5.62B | 10.13%-4.23B | 4.40%-3.12B | -1.21%-1.89B | -3.90%-6.1B | -5.51%-4.71B | -2.42%-3.26B | 0.40%-1.87B | 1.33%-5.88B | 2.42%-4.46B |
Administrative expenses | 0.57%-2.41B | 0.76%-1.76B | -1.12%-1.21B | -2.34%-644.08M | -9.16%-2.42B | -11.89%-1.77B | -12.31%-1.2B | -20.06%-629.33M | -9.15%-2.22B | -7.86%-1.58B |
Research and development expenses | 2.35%-763.77M | 0.17%-578.51M | 2.35%-391.15M | -3.76%-186.14M | 4.55%-782.14M | 12.78%-579.48M | 9.23%-400.57M | 24.90%-179.39M | 6.32%-819.45M | -9.87%-664.39M |
Profit from asset sales | -7.55%11.12M | -52.07%733.1K | -33.40%293K | -93.60%23.28K | 1,643.51%12.03M | 73.40%1.53M | -20.73%439.94K | 4,114.74%363.93K | -0.68%689.82K | -52.53%881.98K |
Revaluation surplus | -36.19%24.65M | 31.79%28.11M | -98.99%445.75K | -41.05%8.24M | 1,175.97%38.64M | 491.21%21.33M | 4,726.36%44.05M | -41.95%13.98M | -101.82%-3.59M | 43.61%-5.45M |
-Changes in the fair value of other assets | -36.19%24.65M | 31.79%28.11M | -98.99%445.75K | -41.05%8.24M | 1,175.97%38.64M | 491.21%21.33M | 4,726.36%44.05M | -41.95%13.98M | -101.82%-3.59M | 43.61%-5.45M |
Impairment and provision | -442.99%-470.58M | 31.34%-92.65M | 13.50%-83.44M | -0.64%-76.26M | -63.12%-86.67M | -129.60%-134.95M | -340.90%-96.47M | -151.25%-75.77M | 56.33%-53.13M | -5.28%-58.77M |
-Other impairment is provision | -442.99%-470.58M | 31.34%-92.65M | 13.50%-83.44M | -0.64%-76.26M | -63.12%-86.67M | -129.60%-134.95M | -340.90%-96.47M | -151.25%-75.77M | 56.33%-53.13M | -5.28%-58.77M |
Special items of operating profit | 5.72%637.09M | -10.44%414.15M | 32.64%341.86M | 103.23%240.71M | -33.16%602.63M | 0.41%462.45M | -31.19%257.75M | 178.83%118.44M | 79.08%901.6M | 79.48%460.54M |
Operating profit | -28.75%3.63B | -15.05%4B | -9.37%3.17B | 4.96%2.43B | 3.86%5.1B | 9.63%4.71B | 9.09%3.49B | 8.52%2.32B | 5.56%4.91B | 3.72%4.3B |
Financing cost | -295.44%-38.23M | -104.66%-2.04M | 50.37%59.67M | -43.52%19.91M | -87.96%19.56M | -73.09%43.84M | -69.34%39.68M | -72.31%35.25M | 22.14%162.46M | 38.05%162.94M |
Adjustment items of earning before tax | 207.57%11.19M | 229.78%4.97M | 653.48%3.31M | -95.91%91.02K | 66.62%-10.4M | 11.74%-3.83M | -349.72%-597.68K | 129.92%2.23M | 50.52%-31.16M | 92.44%-4.34M |
Earning before tax | -29.41%3.61B | -15.71%4.01B | -8.59%3.23B | 4.13%2.45B | 1.33%5.11B | 6.63%4.75B | 6.02%3.53B | 4.03%2.35B | 6.78%5.04B | 5.99%4.46B |
Tax | 28.70%-606.85M | 13.00%-716.6M | 8.11%-561.37M | -8.99%-420.62M | -7.76%-851.17M | -6.67%-823.71M | -4.74%-610.95M | -3.68%-385.93M | -4.75%-789.87M | -10.97%-772.22M |
After-tax profit from continuing operations | -29.55%3B | -16.27%3.29B | -8.68%2.67B | 3.18%2.03B | 0.14%4.26B | 6.62%3.93B | 6.29%2.92B | 4.10%1.97B | 7.17%4.25B | 5.00%3.68B |
Earning after tax | -29.55%3B | -16.27%3.29B | -8.68%2.67B | 3.18%2.03B | 0.14%4.26B | 6.62%3.93B | 6.29%2.92B | 4.10%1.97B | 7.17%4.25B | 5.00%3.68B |
Minority profit | -18.86%165.24M | -5.10%130.46M | 7.21%118.47M | 21.76%73.61M | -29.00%203.65M | -34.65%137.48M | -30.48%110.49M | -29.63%60.45M | 15.15%286.85M | 6.55%210.37M |
Profit attributable to shareholders | -30.09%2.84B | -16.68%3.16B | -9.31%2.55B | 2.59%1.96B | 2.25%4.06B | 9.12%3.79B | 8.54%2.81B | 5.70%1.91B | 6.63%3.97B | 4.91%3.47B |
Basic earnings per share | -30.10%1.744 | -16.68%1.943 | -9.31%1.568 | 2.56%1.204 | 2.25%2.495 | 9.12%2.332 | 8.54%1.729 | 5.67%1.174 | 6.64%2.44 | 4.91%2.137 |
Diluted earnings per share | -30.10%1.744 | -16.68%1.943 | -9.31%1.568 | 2.56%1.204 | 2.25%2.495 | 9.12%2.332 | 8.54%1.729 | 5.67%1.174 | 6.64%2.44 | 4.91%2.137 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | -- | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.